← All diseases
Cancer
Lung cancer (non-small cell)
Do you want to receive a message when there is new research on Lung cancer (non-small cell)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research about Lung cancer (non-small cell) is available. View what Premium costs.
Publications and studies (3193)
- CD103+ tissue-resident T-cells in head and neck squamous cell carcinomas of patients treated anti-PD-1 therapy. (2026/08/05) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model. (2026/08/05) ♡
- CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes. (2026/08/05) ♡
- Dropout after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer in the Veterans Health Administration. (2026/08/05) ♡
- Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report. (2026/08/05) ♡
- Perfluorononanoic acid enhances non-small cell lung cancer progression through CD36-driven fatty acid metabolic reprogramming. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Management of chronic pulmonary GVH in 2025, indication for lung transplantation (SFGM-TC)]. (2026/08/05) ♡
- Efficacy and safety of adjuvant immunotherapy after pathological complete response following neoadjuvant chemoimmunotherapy in patients with resectable NSCLC: A real-world observational study. (2026/08/05) ♡
- TSTScope Unifies Single-Cell Multi-Omics to Identify Functional T Cell States Predictive of Immunotherapy Response. (2026/08/05) ♡
- Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer. (2026/08/04) ♡
- Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Is Associated with Improved Survival in a Longitudinal Cohort. (2026/08/04) ♡
- Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer. (2026/08/03) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee. (2026/08/03) ♡
- Radiomic and clinical predictors of epidermal growth factor receptor mutation in stage IA non-small cell lung cancer. (2026/08/03) ♡
- Engineered tumor cell membrane-coated manganese-amplified STING nanoagonist potentiates PD-L1 blockade immunotherapy in non-small cell lung cancer. (2026/08/03) ♡
- Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer. (2026/08/03) ♡
- Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients. (2026/08/03) ♡
- Biophysical insights into interaction mechanism of cediranib with human serum albumin: In-vitro and in-silico perspectives. (2026/08/03) ♡
- Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance. (2026/08/02) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Too Old for Surgery? A Case Report of an Octogenarian Patient With Locally Advanced Lung Cancer Achieving Long-Term Survival via Bilobectomy Followed by Adjuvant Targeted Therapy. (2026/08/01) ♡
- Network Meta-Analysis of Survival Outcomes With Non-Proportional Hazards Using Flexible M-Splines. (2026/08/01) ♡
- Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF-1α-glycolysis axis to mediate anti-PD-1 resistance in non-small cell lung cancer. (2026/08/01) ♡
- Serum-Based Biomarker Panels are Crucial Tools for the Early Detection of Lung Cancer in High-Risk Individuals in North Indian Population. (2026/08/01) ♡
- [Malnutrition in lung cancer patients : Influence of preoperative nutritional status on the postoperative outcome in patients with non-small cell lung cancer (NSCLC) after curative surgery]. (2026/08/01) ♡
- Chronic pleural effusion one year after lung cancer surgery is associated with non-cancer mortality and postoperative nutritional decline. (2026/08/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis. (2026/08/01) ♡
- Health Insurance Type and Lung Cancer Stage Shift Following Coverage of Screening. (2026/08/01) ♡
- A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy. (2026/08/01) ♡
- Calcium Phosphate Nanoparticle Delivery of siTRIB3 Inhibits EMT and Stemness in NSCLC. (2026/08/01) ♡
- 4-FPAC-Modulated Tumor-Associated Macrophage Conditioned Media Suppresses Malignant Phenotypes and Promotes Cell-Cycle Arrest and Apoptosis in NSCLC. (2026/08/01) ♡
- Sanyang Xuedai enhances radiosensitivity in human non-small cell lung cancer cells through the activation of TLR2 to increase iNOS/NO production-mediated autophagy. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. (2026/08/01) ♡
- Abietane-Type Diterpenoids From Salvia kiangsiensis: Isolation, Semisynthesis, and Cytotoxicity of Their Oxime Ester Derivatives. (2026/08/01) ♡
- Neurological complications induced by checkpoint inhibitors: characterising the clinical spectra. (2026/07/31) ♡
- Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. (2026/07/31) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Osthole and matrine suppress malignant progression of lead-exposed NSCLC via regulating cellular homeostasis: A combined network pharmacology and in vitro experimental study. (2026/07/30) ♡
- Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study. (2026/07/30) ♡
- TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1 : TFAP2A promotes NSCLC radioresistance. (2026/07/30) ♡
- Tumor-Mimetic Microenvironment Primes Cancer Stemness and Drug Resistance through Nucleoskeleton-Mediated Chromatin Remodeling. (2026/07/30) ♡
- Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation. (2026/07/30) ♡
- Phenylalanine- and tryptophan-based hydrazone hybrids targeting the VEGF axis and caspase-mediated apoptosis: Design, synthesis, and biological evaluation. (2026/07/28) ♡
- Synergistic toxicity and clinical prioritization of docetaxel combined with nintedanib for non-small cell lung cancer: a real-world safety analysis using the FAERS database. (2026/07/27) ♡
- Value of serum CEA and CA19-9 dynamic changes and trajectory modeling in prognosis assessment for non-small cell lung cancer. (2026/07/27) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Fatal osimertinib-related interstitial lung disease during adjuvant therapy after left pneumonectomy in a patient with lung adenocarcinoma undergoing maintenance hemodialysis. (2026/07/27) ♡
- Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China. (2026/07/27) ♡
- CT-derived topological intratumoral heterogeneity predicts major pathological response to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer: a two-center study. (2026/07/27) ♡
- Immunological biomarkers for precision stereotactic body radiation therapy in early-stage non-small cell lung cancer: a systematic review. (2026/07/24) ♡
- A novel multivariate framework for functional gene networks enrichment analysis. (2026/07/24) ♡
- A novel photosensitizer (hE26) for photodynamic therapy enhances anticancer efficacy via reactive oxygen species-induced mitochondrial apoptosis in non-small cell lung cancer. (2026/07/24) ♡
- Transitioning from multiport to uniport robot-assisted thoracic surgery: a propensity score-weighted evaluation of safety and feasibility. (2026/07/24) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.